Canaccord raised the firm’s price target on Exagen (XGN) to $8 from $7 and keeps a Buy rating on the shares. The firm said its price target increase is driven by decreased operating expenses in 2027 and beyond and Exagen believes it remains on track to deliver positive adjusted EBITDA in 4Q25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: